BRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers

Reuters

27 Nov 2024

BRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers

Nov 27 (Reuters) - Sellas Life Sciences Group Inc SLS.O:

SELLAS ANNOUNCES POSITIVE DATA FROM PRECLINICAL STUDIES INDICATING ASXL1 MUTATIONS AS PREDICTOR OF RESPONSE TO SLS009 IN SOLID CANCERS
SELLAS LIFE SCIENCES GROUP INC: PRESELECTION METHOD FOR CANCERS RESPONDING TO SLS009
SELLAS LIFE SCIENCES GROUP INC -HIGH EFFICACY OF SLS009 OBSERVED IN 67% OF ASXL1 MUTATED SOLID CANCERS VERSUS 0% IN NON-ASXL1 MUTATED CANCERS
SELLAS: ASXL1 MUTATIONS PREDICTABLY IDENTIFIED IN COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER IN ADDITION TO HEMATOLOGIC MALIGNANCIES

Source text: ID:nGNX2g0W3x

Further company coverage: SLS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/news/2486824886"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486824886\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2486824886?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 21:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486824886","market":"us","top_or_hot":-1,"title":"BRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers</title></head><body><p><span>Nov 27 (Reuters)</span><span> - </span>Sellas Life Sciences Group Inc <span>SLS.O</span>:</p><ul><li><p>SELLAS ANNOUNCES POSITIVE DATA FROM PRECLINICAL STUDIES INDICATING ASXL1 MUTATIONS AS PREDICTOR OF RESPONSE TO SLS009 IN SOLID CANCERS</p></li><li><p>SELLAS LIFE SCIENCES GROUP INC: PRESELECTION METHOD FOR CANCERS RESPONDING TO SLS009</p></li><li><p>SELLAS LIFE SCIENCES GROUP INC -HIGH EFFICACY OF SLS009 OBSERVED IN 67% OF ASXL1 MUTATED SOLID CANCERS VERSUS 0% IN NON-ASXL1 MUTATED CANCERS</p></li><li><p>SELLAS:  ASXL1 MUTATIONS PREDICTABLY IDENTIFIED IN COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER IN ADDITION TO HEMATOLOGIC MALIGNANCIES</p></li></ul><p>Source text: <span>ID:nGNX2g0W3x</span></p><p>Further company coverage: <span>SLS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-27 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid Cancers</title></head><body><p><span>Nov 27 (Reuters)</span><span> - </span>Sellas Life Sciences Group Inc <span>SLS.O</span>:</p><ul><li><p>SELLAS ANNOUNCES POSITIVE DATA FROM PRECLINICAL STUDIES INDICATING ASXL1 MUTATIONS AS PREDICTOR OF RESPONSE TO SLS009 IN SOLID CANCERS</p></li><li><p>SELLAS LIFE SCIENCES GROUP INC: PRESELECTION METHOD FOR CANCERS RESPONDING TO SLS009</p></li><li><p>SELLAS LIFE SCIENCES GROUP INC -HIGH EFFICACY OF SLS009 OBSERVED IN 67% OF ASXL1 MUTATED SOLID CANCERS VERSUS 0% IN NON-ASXL1 MUTATED CANCERS</p></li><li><p>SELLAS:  ASXL1 MUTATIONS PREDICTABLY IDENTIFIED IN COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER IN ADDITION TO HEMATOLOGIC MALIGNANCIES</p></li></ul><p>Source text: <span>ID:nGNX2g0W3x</span></p><p>Further company coverage: <span>SLS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLS","symbol_name":"SELLAS Life Sciences Group Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MY0B1:1","article_id":"2486824886","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486824886","pubTimestamp":1732715238,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid CancersNov 27 (Reuters) - Sellas Life Sciences Group Inc SLS.O:SELL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLS":"SELLAS Life Sciences Group Inc.","BK4139":"生物科技"},"translate_title":"简介-Sellas宣布临床前研究的积极数据表明Asxl1突变是实体癌对SLS009反应的预测因子","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":0.9},"content_text":"BRIEF-Sellas Announces Positive Data From Preclinical Studies Indicating Asxl1 Mutations As Predictor Of Response To SLS009 In Solid CancersNov 27 (Reuters) - Sellas Life Sciences Group Inc SLS.O:SELLAS ANNOUNCES POSITIVE DATA FROM PRECLINICAL STUDIES INDICATING ASXL1 MUTATIONS AS PREDICTOR OF RESPONSE TO SLS009 IN SOLID CANCERSSELLAS LIFE SCIENCES GROUP INC: PRESELECTION METHOD FOR CANCERS RESPONDING TO SLS009SELLAS LIFE SCIENCES GROUP INC -HIGH EFFICACY OF SLS009 OBSERVED IN 67% OF ASXL1 MUTATED SOLID CANCERS VERSUS 0% IN NON-ASXL1 MUTATED CANCERSSELLAS:  ASXL1 MUTATIONS PREDICTABLY IDENTIFIED IN COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER IN ADDITION TO HEMATOLOGIC MALIGNANCIESSource text: ID:nGNX2g0W3xFurther company coverage: SLS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}